Emerging Infectious Diseases (Oct 2017)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

  • Jay Achar,
  • Cathy Hewison,
  • Ana P. Cavalheiro,
  • Alena Skrahina,
  • Junia Cajazeiro,
  • Parpieva Nargiza,
  • Krzysztof Herboczek,
  • Assliddin S. Rajabov,
  • Jennifer Hughes,
  • Gabriella Ferlazzo,
  • James A. Seddon,
  • Philipp du Cros

DOI
https://doi.org/10.3201/eid2310.170303
Journal volume & issue
Vol. 23, no. 10
pp. 1711 – 1713

Abstract

Read online

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

Keywords